The FDA has approved F1CDx, a comprehensive companion diagnostic test that can detect genetic alterations and two genomic signatures in any type of solid tumor. Patients with five common types of advanced cancer can be matched to one of 17 targeted therapies with this single test.
http://ift.tt/2t8wLCX
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου